SLDBHealthcare · BiotechnologySLDB Stock Forecast: Solid Biosciences, Inc. Price Predictions for 2026-2027
The 12 Wall Street analysts covering Solid Biosciences, Inc. hold a median 12-month price target of $16 — +73.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 46 of 100 as at 15 Aug 2026 — in the lower half.
SLDB stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Solid Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (85): The shares have been drifting up relative to others.
Volatility (32): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
SLDB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SLDB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +73.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 June 2026 | HC Wainwright & Co. | Maintains | Buy | $20 → $25 |
| 18 May 2026 | Wedbush | Reiterates | Outperform | — |
| 13 May 2026 | Piper Sandler | Maintains | Overweight | — |
| 13 May 2026 | Wedbush | Maintains | Outperform | — |
| 25 Mar 2026 | JP Morgan | Maintains | Overweight | — |
| 23 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 20 Mar 2026 | Guggenheim | Initiates | Buy | — |
| 20 Mar 2026 | Needham | Reiterates | Buy | — |
| 12 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 12 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 11 Mar 2026 | Wedbush | Reiterates | Outperform | — |
| 9 Feb 2026 | Needham | Reiterates | Buy | — |
| 14 Jan 2026 | Needham | Reiterates | Buy | — |
| 4 Dec 2025 | Needham | Initiates | Buy | — |
| 5 Nov 2025 | Citigroup | Maintains | Buy | — |
| 5 Nov 2025 | JP Morgan | Maintains | Overweight | — |
| 4 Nov 2025 | Barclays | Maintains | Overweight | — |
| 4 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 14 Aug 2025 | Chardan Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SLDB appears on the weeks it earns a place.
SLDB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Solid Biosciences, Inc. (SLDB) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.2×
- Price / sales
- —
- Price / book
- 2.6×
- EV / EBITDA
- −3.0×
Cheaper than 73% of US stocks
Cheaper than 39% of US stocks
Cheaper than 74% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −65.5%
- Return on assets
- −36.4%
- Dividend yield
- —
Higher than 18% of US stocks
Higher than 12% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
SLDB vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Solid Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about SLDB stock
What is the SLDB stock price forecast for 2026-2027?
The 12 Wall Street analysts covering Solid Biosciences, Inc. have a median 12-month price target of $16, with estimates ranging from $11 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SLDB stock a buy right now?
Of the 12 analysts covering Solid Biosciences, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Solid Biosciences, Inc. 46 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SLDB?
As at 15 Aug 2026, Solid Biosciences, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (85 of 100).
Will SLDB stock go up?
No one can know that. What the data says: the median 12-month target from 12 analysts implies +73.9% from the last close, and Ticker Nerd's factor model ranks Solid Biosciences, Inc. 46 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SLDB stock forecast for 2030?
No analyst covering Solid Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SLDB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $26 over the next 12 months.
How has SLDB stock performed over the past year?
Solid Biosciences, Inc. returned +49.1% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Solid Biosciences, Inc. do?
Solid Biosciences Inc. is a precision genetic medicine company developing gene therapies for rare neuromuscular and cardiac diseases.
About Solid Biosciences, Inc.
Solid Biosciences Inc. is a precision genetic medicine company developing gene therapies for rare neuromuscular and cardiac diseases. Its lead candidate, SGT-003, targets Duchenne muscular dystrophy and is in phase 1/2 clinical trials. The company advances a diversified pipeline including SGT-212 for Friedreich's ataxia in phase 1b trials, SGT-501 for catecholaminergic polymorphic ventricular tachycardia in preclinical development, SGT-601 for TNNT2-mediated dilated cardiomyopathy, SGT-401 for BAG3-mediated dilated cardiomyopathy, and SGT-701 for RBM20-related cardiomyopathy in discovery. Solid Biosciences also develops enabling platform technologies such as capsid libraries, genetic regulators, immunomodulation approaches, and dual gene expression systems to enhance gene therapy delivery. These innovations support its pipeline and potential collaborations in the biotechnology sector focused on genetic medicines for devastating conditions. Founded in 2013 and headquartered in Charlestown, Massachusetts, Solid Biosciences emphasizes patient-centered approaches in advancing therapies for unmet needs in neuromuscular and cardiac disease markets.
CEO Mr. Alexander G. Cumbo · 121 employees · United States · https://www.solidbio.com